GW Pharmaceuticals PLC (GWP.L)
-LSE 47.65 
1.90(4.15%) 8:47AM EDT
| Prev Close: | 45.75 |
|---|
| Open: | 45.50 |
|---|
| Bid: | 46.00 |
|---|
| Ask: | 48.00 |
|---|
| 1y Target Est: | 122.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 45.50 - 47.65 |
|---|
| 52wk Range: | 39.39 - 85.00 |
|---|
| Volume: | 97,619 |
|---|
| Avg Vol (3m): | 137,991 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- Canaccord Genuity Initiates Coverage on GW Pharmaceuticals (NASDAQ:GWPH) (AIM:GWP) with a Buy Recommendation - Video Posted on InvestmentPitch.comThomson Reuters ONE(Wed, Jun 5)
- Interim 2013 GW Pharmaceuticals PLC Earnings Release - Before Market OpenCCBN(Mon, Jun 3)
- BRIEF-GW Pharma swings to net profit in first halfat Reuters(Mon, Jun 3)
- GW Pharmaceuticals plc Reports 2013 Second Quarter Financial ResultsPR Newswire(Mon, Jun 3)
- GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013PR Newswire(Tue, May 14)
- GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global MarketPR Newswire(Wed, May 8)
- BRIEF-GW Pharma wins Italian approval for cannabinoid drugat Reuters(Tue, May 7)
- GW Pharmaceuticals plc Announces Sativex® Commercialization Approval in ItalyPR Newswire(Tue, May 7)
- GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global MarketPR Newswire(Wed, May 1)
- BRIEF-GW gets U.S. patent allowance for Sativex formulation sprayat Reuters(Mon, Apr 22)
- BRIEF-GW Pharma says UK eases restrictions on sativexat Reuters(Wed, Apr 10)
- BRIEF-GW Pharma gets new US patent allowance for delivery of Sativexat Reuters(Wed, Apr 3)
- GW Pharmaceuticals Files Registration Statement for NASDAQ Global Market Listing and U.S. Initial Public OfferingPR Newswire(Tue, Mar 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | -3.29 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forGWP.L.